SOX as Salvage Treatment in Nasopharyngeal Carcinoma
SOX as Salvage Treatment in Nasopharyngeal Carcinoma
The aim of the study is to evaluate the efficacy and safety of SOX regimen (S-1 plus
 oxaliplatin) as salvage treatment in patients with relapsed or metastatic nasopharyngeal
 carcinoma.
The treatment option in patients with platinum-resistant relapsed or metastatic
 nasopharyngeal carcinoma is limited. Previous studies showed that both S-1 and oxaliplatin
 were effective in head and neck cancer. Moreover, SOX (S-1 plus oxaliplatin) was proved to be
 tolerable in advanced stage gastric cancer. Therefore, we aim to evaluate this regimen in
 salvage setting of nasopharyngeal carcinoma.
Inclusion Criteria:

 -  Age range: 18-75 years old

 -  Histological confirmed incurable relapsed or metastatic nasopharyngeal carcinoma

 -  Prior exposure of at least one line of platinum-containing regimen

 -  ECOG performance status 0-1

 -  Life expectancy of more than 3 months

 -  Bone marrow function: ANC≧1.5×109/L, PLT≧100×109/L, Hb≧80g/L

 -  Liver function: total bilirubin, ALT and AST <1.5×UNL

 -  Renal function: Cr<1.5×UNL, CCR≧50ml/min

 -  Without > 1 grade of neuropathy

 Exclusion Criteria:

 -  With curable treatment option

 -  With CNS involvement

 -  Prior platinum exposure only in neo-adjuvant/adjuvant setting or concurrently used
 with radiotherapy

 -  Treated with > 2 lines of palliative chemotherapy

 -  With prior exposure of S-1 or oxaliplatin

 -  History of other malignancies except cured basal cell carcinoma of skin and carcinoma
 in-situ of uterine cervix

 -  Significant active infection

 -  Pregnant or lactating women